MOTS-c

What MOTS-c does

MOTS-c is a small peptide the body makes. People use injections hoping for better energy, exercise performance or fat loss. Human research mostly measures natural peptide levels; a new dosing trial has no posted results. Injection safety and effective doses remain unknown.

• In mice, it reduced diet-related weight gain and insulin resistance. (animal)
• In mice, it improved physical ability, even when treatment began in old age. (animal)
• People report more energy and easier workouts, but no published dosing trial in people shows this. (Reported by users)

Uses in the sources

• Users report more energy; no published native MOTS-c dosing trial establishes this effect. (Reported by users) (source)
• People report easier workouts and use before training. Controlled human injection results are absent. (Reported by users) (source)
• Self-reported fat-loss claims rely on uncontrolled experience; mouse weight results do not establish human weight loss. (Reported by users) (source)

MOTS-c dosage

Typical reported dose: 5 mg every 5 days

• 5 mg every 5 days: 5 mg every 5 days every 5 days, under the skin. Reported by users, occasional report. Studied in: Adults reporting self-use online; age and product identity are not independently verified. (source)
• 10 mg once weekly: 10 mg once weekly once weekly, under the skin. Reported by users, rare report. Studied in: Adults reporting self-use online; age and product identity are not independently verified. (source)
• 3 mg daily report: 3 mg daily daily, under the skin. Reported by users, rare report. Studied in: Adults reporting self-use online; age and product identity are not independently verified. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

How to mix MOTS-c

Comes as: Lyophilized powder vial, community-reported.

Mixed with: Bacteriostatic water is reported by users; no approved diluent or reconstitution label exists..

Common vial sizes: 10, 40 mg. Common water amounts: 1, 2 mL.

• A 10 mg vial with 1 or 2 mL water appears in forum discussions; 40 mg with 2 mL is a separate report.
• These volumes describe reports and concentration math, not a tested stability or sterility procedure.
• A short blood half-life does not establish how long peptide remains stable in a vial.

Before mixing: Users report refrigeration of sealed powder vials; shelf life is not validated across products.

After mixing: No validated home-mixed shelf life. Forum claims of only hours or weeks are not reliable stability data.

MOTS-c side effects and risks

Reported side effects

• Sleep disruption or feeling overstimulated: Forum reports only; no denominator or reliable rate., moderate. Stop use and review new insomnia or stimulation with a clinician. (source)
• Immune or allergic reactions: FDA identifies a potential risk; native peptide human incidence is unknown., serious. Breathing difficulty or swelling requires emergency care. (source)
• Injection-related infection or contamination: General unapproved injectable risk; no MOTS c specific rate., serious. Seek care for spreading redness, heat, pain or fever. (source)
• Painful or itchy injection-site swelling: Several forum comments; no reliable rate or confirmed product identity., moderate. Stop exposure and seek review for persistent swelling; breathing symptoms need emergency care. (source)

Stop and get help if

• Trouble breathing, throat or tongue swelling, collapse: Stop exposure and call emergency services now. Use prescribed adrenaline if available.
• Spreading hot, painful injection-site redness, especially with fever: Stop injections and seek same-day care; confusion or fainting needs emergency care.
• Confusion, seizure, collapse or low blood sugar that does not resolve: Call emergency services for severe symptoms; follow the established diabetes rescue plan if applicable.

Who should avoid it

• pregnant: Precaution: no administered-peptide pregnancy safety data were identified.
• breastfeeding: Precaution: transfer into milk and effects on a nursing infant are unknown.
• tryingToConceive: Precaution: human fertility and embryo safety after injected peptide are unknown.
• under18: Precaution: no pediatric dosing or injection-safety data were identified.
• diabetes: Glucose effects and interactions with diabetes medicines are untested in humans.
• kidneyDisease: Human clearance and dose adjustment in kidney disease have not been established.
• liverDisease: Human exposure and dose adjustment in liver disease have not been established.
• heartCondition: Cardiac biomarker studies do not establish injection safety in people with heart disease.
• surgeryPlanned: Tell the care team about use; perioperative drug interactions and safety are unknown.
• activeCancer: No clinical cancer-treatment interaction data exist; laboratory effects cannot predict safety during cancer care.
• testedAthlete: Prohibited at all times under WADA 2026 S4.4.1, metabolic modulators.

Interactions

• Insulin and sulfonylureas: Possible added glucose lowering is theoretical. No human interaction study has measured the risk.
• Metformin and other glucose-lowering medicines: Combination effects on glucose, appetite and exercise tolerance are untested for injected MOTS-c.
• Anticoagulants and antiplatelets: No compound-specific interaction is established. Review injection-related bleeding risk with the prescriber.
• Other mitochondrial peptides: No human trial establishes the safety or benefit of stacking mitochondrial peptides. HNG is not native humanin.

Product quality risks

• Unapproved injectable products can have too much, too little or none of the stated ingredient.
• Possible contaminants include microbes, endotoxins, solvents, metals and particles; risk varies by batch.
• No independent market-wide test of native MOTS-c or humanin products was identified.

What to expect

Endogenous biomarker measurements, registrations without results and administration of the CB4211 analogue do not establish direct human MOTS-c results. A direct-administration evidence level is not established here.

Key studies

• Kidney failure and stress signals: Circulating mitochondrial peptides were lower in kidney failure; MOTS-c was inversely linked to the AGE/sRAGE ratio. (source)
• Exercise in cerebral palsy: Natural peptide levels were similar at rest; a 45-minute run caused no or modest changes across groups. (source)
• Hashimoto's thyroiditis: MOTS-c was lower in Hashimoto's thyroiditis, p<0.001. Levothyroxine use was not linked to different levels. (source)
• Atrial fibrillation biomarkers: Atrial tissue humanin and MOTS-c were lower in atrial fibrillation; plasma MOTS-c was also lower. (source)
• Kidney transplant biomarkers: Median MOTS-c was 178 vs 142 ng/mL, p=0.014. It was not significantly linked to cardiovascular disease or mortality. (source)
• Dialysis and arterial stiffness: Urinary MOTS-c correlated with arterial stiffness, r=0.708, p=0.001; dialysate MOTS-c correlated inversely, r=-0.717, p=0.019. (source)

MOTS-c FAQ

• Is MOTS-c FDA-approved? No. MOTS-c acetate: limited to subcutaneous, intramuscular forms. The October 30, 2026 Federal Register describes a nonbinding draft interim HHS 503A enforcement policy, with public comment invited. It is conditional on eligible state-licensed pharmacies, federal facilities or licensed physicians, a patient-specific prescription, a single active ingredient, specified identity and route, qualified manufacturing, lot testing, reporting and labeling conditions. It is not FDA drug approval, a final 503A listing or general authorization to supply research products.
• How do people take it? Under the skin, every 5 days. A 20-day course, repeated 6 months after the first course ends. 20 days. Source: reported by users, not an established dose.
• What's the difference between MOTS-c and SS-31 (elamipretide)? MOTS-c: a peptide the body makes; injection benefits and safety remain unproven. SS-31 (elamipretide): a peptide approved for Barth syndrome muscle strength; benefit needs confirmation and broader energy benefits remain unproven. Why people pair them: users describe an SS-31 course before MOTS-c for hoped-for mitochondrial support.
• Can I take it with SS-31 / elamipretide? Users describe an SS-31 course before MOTS-c for hoped-for mitochondrial support. No human trial has tested this combination; safety and added benefit are unknown. Source: reported by users. Ask a doctor before combining anything.
• Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). Named as an AMPK activator among metabolic modulators.
• How long does a mixed vial last? No validated home-mixed shelf life. Forum claims of only hours or weeks are not reliable stability data.